Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen

Clinical Chemistry

Volumn 44, Issue 11, 1998, Pages 2281-2289

  Rosenquist, Christian ^a   Fledelius, Christian ^a   Christgau, Stephan ^a   Pedersen, Brian J ^a   Bonde, Martin ^a   Qvist, Per ^a   Christiansen, Claus ^b  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OSTEOLYSIS; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN URINE LEVEL;

EID: 0031786307     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.11.2281     Document Type: Article

References (30)

1. Burgeson RE. New collagens, new concepts. Annu Rev Cell Biol 1988;4:552-77.
2. Black D, Duncan A, Robins SP. Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversephase high performance liquid chromatography. Anal Biochem 1988;169:197-203.
3. Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MJ. Direct enzyme-linked immunoassay for urine dexoypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 1994;9:1643-9.
4. Hanson DA, Wies MAE, Bollen A-M, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992;7:1251-8.
5. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine. Clin Chem 1994;40:2022-5.
6. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 1995;80:864-8.
7. Garnero P, Gineyts E, Riou JP, Delmas PD. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 1994;79: 780-5.
8. Risteli J, Elonaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptides of type I collagen. A new marker of bone col lagen degradation. Clin Chem 1993;39:635-40.
9. Bonde M, Garnero P, Fledelius C, Qvist P, Delmas PD, Christiansen C. Measurement of bone degradation products in serum using antibodies reactive with isomerized form of an 8 amino acid sequence of the C-telopeptide of Type I collagen. J Bone Miner Res 1997;12:1028-34.
10. Clemens JD, Herrick MV, Singer FR, Eyre DR. Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem 1997;43:2058-63.
11. Soinila S, Mpitsos GJ, Soinila J. Immunohistochemistry of enkephalins: model studies an hapten-carrier conjugates and fixation methods. J Histochem Cytochem 1992;40:231-9.
12. Kearny JF, Radbruch A, Liesegang B, Rajewsky K. A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J Immunol 1979;123:1548-50.
13. Meyer KH, Behringer DM, Veh RW. Antibodies against neuroactive amino acids and neuropeptides. I. A new two-step procedure for their conjugation to carrier proteins and the production of an anti-Met-enkephalin antibody reactive with glutaraldehyde-fixed tissues. J Histochem Cytochem 1991;39:749-60.
14. Rosenquist C, Bonde M, Fledelius C, Qvist P. A simple enzyme-linked immunosorbent assay of human osteocalcin. Clin Chem 1994;40:1258-64.
15. Fledelius C, Johnsen AH, Cloos PAC, Bonde M, Qvist P. Characterization of urinary degradation products derived from type I collagen. J Biol Chem 1997;272:9755-63.
16. Nakane PK, Kawaoi A. Peroxidase-labelled antibody. A new method of conjugation. Histochem Cytochem 1974;22:1084-91.
17. Glick MR, Ryder KW, Glick SJ. Interferographs. User's guide to interferences in clinical chemistry instruments, 2nd ed. Indianapolis, IN: Science Enterprises Inc., 1991:8-13.
18. SAS/STAT. Guide for personal computers, 6th ed. Cary, NC: SAS Institute Inc., 1987:941-8.
19. Fledelius C, Kolding I, Qvist P, Bonde M, Hassager C, Reginster JY, et al. Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide alpha 1 chain of type I collagen. Application in an enzyme immunoassay and comparison to CrossLaps ELISA. Scand J Clin Lab Investig 1997;57:73-83.
20. Prockop DJ, Kivirikko KI. Collagens: molecular biology, diseases, and potentials for therapy. Annu Rev Biochem 1995;64:403-34.
21. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995;332:305-11.
22. Delmas PD, Wahner HW, Mann KG, Riggs BL. Assessment of bone turnover in postmenopausal osteoporosis by measurement of serum bone Gla-protein. J Lab Clin Med 1983;102:470-6.
23. Garnero P, Gineyts E, Riou JP, Delmas PD. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 1994;79: 780-5.
24. Riis BJ. The role of bone loss. Am J Med 1995;98:29S-32S.
25. Christgau S, Rosenquist C, Alexandersen P, Hannover N, Ravn P, Pedersen BJ, et al. Clinical evaluation of the serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of degradation products derived from the C-terminal telopeptide of type I collagen. Clin Chem 1998;44:2302-12.
26. Charles P, Mosekilde L, Risteli L, Risteli J, Eriksen EF. Assessment of bone remodeling using biochemical indicators of type I collagen synthesis and degradation: relation to calcium kinetics. Bone Miner 1994;24:81-94.
27. Pedrazzoni M, Alfano FS, Gatti C, Fantuzzi M, Girasole G, Campanini C, et al. Acute effects of bisphosphonates on new and traditional markers of bone resorption. Calcif Tissue Int 1995;57: 25-9.
28. Blumsohn A, Naylor KE, Assiri AM, Eastell R. Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease. Clin Chem 1995;41:1592-8.
29. Hassager C, Jensen LT, Podenphant J, Thomsen K, Christiansen C. The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decanoate and hormone replacement therapy. Calcif Tissue Int 1994;54:30-3.
30. Risteli J, Sassi M-L, Eriksen H, Niemi S, Mansell JP, Risteli L. Epitope of the assay for the carboxyterminal telopeptide of human type I collagen (ICTP)[Poster]. J Bone Miner Res 1997;12(Suppl 1):S583.